1. Introduction {#sec1-marinedrugs-15-00020}
===============

Gliomas, the most common group of primary brain tumors, are subcategorized into astrocytomas, oligodendrogliomas and ependymomas. According to World Health Organization (WHO), glioblastoma multiforme (GBM), the most malignant and lethal form of brain tumor in adults, is a grade IV astrocytoma with very high morbidity and mortality. The disease has a very poor prognosis with short median survival, only about 15 months, despite current multimodal treatment including maximal surgical resection if feasible, followed by a combination of radiotherapy and/or chemotherapy \[[@B1-marinedrugs-15-00020]\]. Therefore, it is imperative to present new and more effective therapeutic interventions to better control GBM.

In fact, the short median survival of GBM is largely ascribed to the inevitable tumor recurrence. Recent research has paid more attention to the existence of glioma stem cells (GSCs), which are a subgroup of tumor cells with properties that resemble those of neural stem cells, and are able to drive tumorigenesis and likely contribute to rapid tumor recurrence \[[@B2-marinedrugs-15-00020]\]. These cells were first described more than ten years ago and have been demonstrated with the capability of multi-lineage differentiation, self-renewal and extensive proliferation \[[@B3-marinedrugs-15-00020]\]. In addition, GSCs can endure and even thrive in stressful tumor conditions, including hypoxia, oxidative stress, inflammation, acidic stress, and low glucose \[[@B4-marinedrugs-15-00020]\]. Moreover, their resistance to conventional therapy and promotion of tumor angiogenesis also influence clinical practice \[[@B5-marinedrugs-15-00020],[@B6-marinedrugs-15-00020]\]. Thus, GSCs provide new insight into the strategy in GBM therapy.

Three-dimensional growth model, a growth sphere formed by cancer stem cells under specific culture conditions in vitro, is a more reasonable model for tumor biology and drug screening in vitro studies \[[@B7-marinedrugs-15-00020],[@B8-marinedrugs-15-00020]\]. Likewise, GSCs also have the characteristic of forming spheres and clinical data show that the rates of existence of gliomaspheres were more prominent in high grade malignant gliomas \[[@B9-marinedrugs-15-00020]\]. Previously, we isolated gliomaspheres from U251 glioma cell lines and tried to apply it for drug screening. We found that there were undifferentiated GSCs and differentiated cancer cells with different differentiation degrees in gliomaspheres, which were similar to the growth state of glioma in vivo \[[@B10-marinedrugs-15-00020]\]. Our previous data showed that gliomaspheres express stem cell biomarkers nestin and CD133, which are certain phenotypes of GSC, and tachyplesin I inhibited the viability and proliferation of gliomaspheres dose dependently, by damaging the plasma membrane and inducing differentiation of GSCs \[[@B11-marinedrugs-15-00020]\]. These findings indicate that tachyplesin I is a potential anti-tumor drug which may be used in GBM therapy.

Tachyplesin I, a cationic peptide with 17 residues (NH~2~-K-W-C-F-R-V-C-Y-R-G-I-C-Y-I-R-R-C-R-CONH~2~), was originally isolated from hemocytes of the horseshoe crab (*Tachypleus tridentatus*) \[[@B12-marinedrugs-15-00020]\]. It has the ability of anti-enzymatic hydrolysis due to two disulfide-stabilized β-hairpins \[[@B13-marinedrugs-15-00020]\]. Several studies have demonstrated that tachyplesin I can inhibit the proliferation and affect the differentiation of tumor cells, such as hepatocarcinoma, gastric adenocarcinoma and leukemia \[[@B14-marinedrugs-15-00020],[@B15-marinedrugs-15-00020]\]. This peptide has also been demonstrated to activate the classic complement pathway to lyse and kill tumor cells and to alter the expression of tumor suppressor genes and oncogenes to induce cell differentiation and reverse the malignant phenotype \[[@B16-marinedrugs-15-00020],[@B17-marinedrugs-15-00020]\]. Most interestingly, the negatively charged components of cancer cells, which are quite different from neutral normal cells, are more vulnerable by the positively charged cationic peptides, including tachyplesin I. The electrostatic attraction between cancer cells and cationic peptides is believed to play a major role in the selective disruption of cancer cell membranes, which avoids traditional mechanism of drug resistance \[[@B18-marinedrugs-15-00020]\].

Although the anti-tumor effect of tachyplesin I has been studied to some extent, the mechanism of anti-tumor activity in GBM is largely unknown. In recent years, proteomics has been shown to be a powerful approach for exploring the molecular mechanisms of anti-tumor drugs. In this study, our primary goal was to identify the changes in protein expression profile of U251 gliomaspheres under the treatment of tachyplesin I, which may help us to better understand the molecular mechanisms underlying potential anti-glioma drugs. Here, both gel-based and shotgun proteomic approaches were performed to gain a higher proteome coverage and better quantification results \[[@B19-marinedrugs-15-00020]\]. Proteomic analysis using two dimension difference gel electrophoresis (2D-DIGE) and stable isotope dimethyl labeling based Liquid chromatography--mass spectrometry/mass spectrometry (LC-MS/MS) revealed that 192 proteins were differentially expressed in U251 gliomaspheres in response to tachyplesin I. Biological involvement of these proteins are further discussed in detail through signaling pathways and protein--protein interaction network analysis. Furthermore, the expression of cathepsins in lysosomes and TOP2A was further validated by Western blot and PRM, due to their important involvement in the anti-tumor activity of tachyplesin I, by inhibiting migration and promote apoptosis of glioma cells, respectively.

2. Results {#sec2-marinedrugs-15-00020}
==========

2.1. Protein Expression Profile of Tachyplesin I Treated U251 Gliomaspheres Using 2D-DIGE Analysis {#sec2dot1-marinedrugs-15-00020}
--------------------------------------------------------------------------------------------------

The 2D-DIGE images, which were scanned at the wavelengths of 488/520, 532/580, and 633/670 nm, visualize the protein expression pattern in the cells ([Figure 1](#marinedrugs-15-00020-f001){ref-type="fig"}A). In the image analysis, 1298 protein spots were detected. Of these, 35 spots with fold change larger than ±1.5 were considered significantly altered in tachyplesin I treated U251 gliomaspheres compared with untreated control ([Figure 1](#marinedrugs-15-00020-f001){ref-type="fig"}B). Among the protein spots that satisfied the statistical criteria, 26 were confidently identified by MALDI-TOF/TOF analysis. Out of 26 identified proteins, 13 were up-regulated while the others were down-regulated in tachyplesin I treated U251 gliomaspheres. Up-regulated proteins were mainly involved in regulation of cell cycle and apoptosis, and cytoskeleton proteins ([Table 1](#marinedrugs-15-00020-t001){ref-type="table"}). Conversely, down-regulated proteins were involved in glycolysis, response to stimulus and calcium or ion binding ([Table 1](#marinedrugs-15-00020-t001){ref-type="table"}). Several proteins (Vimentin, Phosphate carrier protein, mitochondrial and Guanine nucleotide-binding protein G(q) subunit alpha) were identified more than once in different location of 2D-DIGE gel, suggesting diverse protein isoforms, such as the occurrence of post-translational modification. Representative images of one up-regulated protein endothelin-converting enzyme 1 (ECE1) and one down-regulated protein alpha-enolase (ENO1) in different dose groups are shown in [Figure 1](#marinedrugs-15-00020-f001){ref-type="fig"}C. Western blot assay was performed to confirm the results obtained from 2D-DIGE experiment and the results were consistent ([Figure 1](#marinedrugs-15-00020-f001){ref-type="fig"}C).

2.2. Relative Quantification Using Dimethyl Labeling Based LC-MS/MS Analysis {#sec2dot2-marinedrugs-15-00020}
----------------------------------------------------------------------------

Peptide samples from the control, and 10 μg/mL and 40 μg/mL tachyplesin I-treated U251 gliomaspheres were labeled with dimethyl stable isotope tags. To obtain reliable quantification results, we conducted one forward and one reverse dimethyl labeling experiments. A total of 74,240 peptides from 4891 proteins were identified in the forward-labeling samples and 73,892 peptides from 4854 proteins in the reverse-labeling samples ([Supplementary Materials Tables S1--S4](#app1-marinedrugs-15-00020){ref-type="app"}). In both forward and reverse labeling experiment, the labeled peptides account for more than 99.8% of total identified peptides, indicating a good labeling efficiency. A total of 5737 proteins were reliably quantified in both the forward and reverse labeling experiments, of which 4008 proteins were overlapped ([Figure 2](#marinedrugs-15-00020-f002){ref-type="fig"}B). The protein ratios of L/H and M/H in the forward labeling experiment and protein ratios of M/L and H/L in the reverse labeling experiment indicate the relative abundance of proteins in 10 μg/mL and 40 μg/mL tachyplesin I-treated groups compared to the control. The log~2~ transformed protein ratios between two different experimental groups all form a symmetric distribution curve with the peak around zero (the original ratio = 1) ([Figure 2](#marinedrugs-15-00020-f002){ref-type="fig"}A), and proteins that were increased or decreased in the forward-labeling experiment were also increased or decreased in the reverse-labeling experiment ([Figure 2](#marinedrugs-15-00020-f002){ref-type="fig"}C), suggesting that there was no bias in the labeling and LC-MS experiments. Only those proteins with fold changes \>2 and quantified in both forward and reverse labeling experiments were reported as differentially expressed proteins. Among 4088 proteins, the expression levels of 166 were significantly altered by tachyplesin I treatment. Among them, 55 were up-regulated ([Table 2](#marinedrugs-15-00020-t002){ref-type="table"}) while 111 proteins were down-regulated ([Table 2](#marinedrugs-15-00020-t002){ref-type="table"}). [Figure 2](#marinedrugs-15-00020-f002){ref-type="fig"}D shows representative mass spectrometric results for the identification and quantification of the peptide DPDAQPGGELMLGGTDSK from cathepsin D, which clearly reveals the down-regulation of this protein in both sets of experiments.

2.3. Cellular Functions of Differentially Expressed Proteins and Associated Pathways {#sec2dot3-marinedrugs-15-00020}
------------------------------------------------------------------------------------

Systematic gene ontology (GO) analysis of 192 differentially expressed proteins identified from both 2D-DIGE and dimethyl labeling proteomic approaches was performed using PANTHER and DAVID tools. Molecular function analysis revealed that the majority of the differentially expressed proteins demonstrated catalytic (42.93%), binding (26.18%) and structural molecule activities (10.99%) ([Figure 3](#marinedrugs-15-00020-f003){ref-type="fig"}A). The biological processes altered by tachyplesin I treatment were most involved in metabolic processes (30.13%), cellular processes (19.88%), developmental processes (8.43%), localization (8.43%) and biological regulation (8.13%) ([Figure 3](#marinedrugs-15-00020-f003){ref-type="fig"}B). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways including lysosome pathway (15 proteins), glycosaminoglycan degradation pathway (6 proteins), antigen processing and presentation pathway (8 proteins), DNA replication pathway (5 proteins), type I diabetes mellitus pathway (4 proteins) and glycolysis/gluconeogenesis pathway (4 proteins) are the top pathways altered in response to tachyplesin I treatment ([Table 3](#marinedrugs-15-00020-t003){ref-type="table"}).

2.4. Tachyplesin I Influences Metabolic Process and Alters the Expressions of Cytoskeleton Proteins {#sec2dot4-marinedrugs-15-00020}
---------------------------------------------------------------------------------------------------

In our study, altered proteins involved in metabolic process occupied major share. Of which, glycolytic/gluconeogenesis enzymes including alpha-enolase (ENO1), gamma-enolase (ENO2), triosephosphate isomerase (TPI1) and phosphoglycerate kinase 1 (PGK1) were found to be down-regulated in response to tachyplesin I treatment. In addition, tachyplesin I treatment on U251 gliomaspheres changed the expression of cytoskeleton proteins. Eighteen out of 192 altered proteins induced by tachyplesin I were classified into cytoskeleton protein class in PANTHER classification system. Several cytoskeleton proteins such as spectrin beta chain, non-erythrocytic 2 (SPTBN2), keratin, type II cytoskeletal 1 (KRT1), keratin, type II cytoskeletal 2 epidermal (KRT2), keratin, type I cytoskeletal 9 (KRT9), keratin, type I cytoskeletal 10 (KRT10), vimentin (VIM), ezrin (EZR), interferon-induced GTP-binding protein Mx1 (MX1), interferon-induced GTP-binding protein Mx2 (MX2), cysteine and glycine-rich protein 1 (CSRP1), elongation factor 1-gamma (EEF1G) and tubulin beta-2B chain (TUBB2B) were down-regulated ([Table 2](#marinedrugs-15-00020-t002){ref-type="table"}) while neurofilament light polypeptide (NEFL), nestin (NES), kinesin-like protein KIF11 (KIF11), tropomyosin alpha-4 chain (TPM4), dystonin (DST) and LIM and cysteine-rich domains protein 1 (LMCD1) were observed with up-regulation ([Table 2](#marinedrugs-15-00020-t002){ref-type="table"}). To some extent, all these downstream effects of tachyplesin I contribute to its anti-tumor activity.

2.5. Tachyplesin I Reduces Expressions of Several Lysosomal Acid Hydrolases {#sec2dot5-marinedrugs-15-00020}
---------------------------------------------------------------------------

As shown in [Figure 4](#marinedrugs-15-00020-f004){ref-type="fig"}A, consistent with the results of proteomic analysis, protein level of lysosomal protective protein (CTSA) was verified to be down-regulated by tachyplesin I using Western blot. Further, other family members of cathepsins, including cathepsin B (CTSB) and cathepsin D (CTSD), as well as cathepsin A (CTSA) were analyzed by PRM mass spectrometry with three technical replicates. For each protein, two unique peptides were selected and monitored for quantification. The skyline software was used to extract the peak areas (area under the curve, AUC) of six to seven strongest transition ions for each peptide ([Supplementary Materials Table S5](#app1-marinedrugs-15-00020){ref-type="app"}). The normalized sum AUC of all the transitions for each peptide are showed in [Figure 4](#marinedrugs-15-00020-f004){ref-type="fig"}B, which demonstrates that two unique peptides derived from the same protein have a consistent trend, and variations among different technical replicates are small. The results of PRM analysis showed that tachyplesin I down-regulated the levels of CTSA, CTSB and CTSD, which are consistent with dimethyl labeling results.

2.6. Protein-Protein Interaction Network of Differentially Expressed Proteins {#sec2dot6-marinedrugs-15-00020}
-----------------------------------------------------------------------------

Protein--protein interaction (PPI) network was established based on the total 192 differentially expressed proteins related to tachyplesin I treatment, including 26 proteins found in 2D-DIGE analysis and 166 proteins found in dimethyl labeling-based LC-MS analysis. Among them, 180 proteins could connect into a network through direct interaction or an intermediate partner at the PPI level ([Figure 5](#marinedrugs-15-00020-f005){ref-type="fig"}A). Interestingly, DNA topoisomerase 2-alpha (TOP2A) seemed to be the crucial protein in the effects of tachyplesin I as it has the most numerous connections and forms the most complex link with other proteins in the signal network ([Figure 5](#marinedrugs-15-00020-f005){ref-type="fig"}B).

2.7. Confirmation of the Involvement of TOP2A in the Effects of Tachyplesin I and Correlation with Clinical Prognosis in TCGA Database {#sec2dot7-marinedrugs-15-00020}
--------------------------------------------------------------------------------------------------------------------------------------

Western blot result ([Figure 5](#marinedrugs-15-00020-f005){ref-type="fig"}C) showed that the expression level of TOP2A was dose-dependent increased after treatment of tachyplesin I, which was consistent with the result of dimethyl labeling based LC-MS/MS analysis ([Table 2](#marinedrugs-15-00020-t002){ref-type="table"}). At the same time, the expression level of TOP2A was also checked by PRM analysis. As shown in [Figure 5](#marinedrugs-15-00020-f005){ref-type="fig"}D, after tachyplesin I treatment, the expression level of TOP2A was up-regulated, which verified the data obtained from dimethyl labeling based quantification. Then, we used cBioPortal tool to analyze the relationship between the mRNA transcript level of TOP2A and clinical prognosis of GBM patients based on TCGA database to examine the effects of tachyplesin I by targeting on TOP2A. As shown in [Figure 5](#marinedrugs-15-00020-f005){ref-type="fig"}E, patients with alterations in TOP2A at mRNA transcript level have a better prognosis compared with those without alterations in TOP2A. The analysis showed a significantly better overall and disease-free survival of patients with over-expression of TOP2A.

3. Discussion {#sec3-marinedrugs-15-00020}
=============

More and more studies have shown that certain cationic antimicrobial peptides (AMPs), which are toxic to bacteria but not to normal mammalian cells, exhibit a broad spectrum of cytotoxic activity against cancer cells \[[@B20-marinedrugs-15-00020]\]. Tachyplesin I, which is isolated from hemocytes of the horseshoe crab, has been identified as a member of AMPs and exhibits cytotoxic activity against cancer cells. However, it is uncertain why only some types of AMPs get kill cancer cells, while others not. Besides, whether the molecular mechanisms underlying the antitumor and antimicrobial activities are the same or not remains unclear. Through this study we aim to identify the protein targets of tachyplesin I in U251 gliomaspheres by carrying out a large-scale proteome analysis, which can help us to better understand the molecular mechanisms underlying AMPs as potential anti-glioma drugs.

In this study, gel-based 2D-DIGE and stable isotope dimethyl labeling based LC-MS/MS analysis were combined to reveal the alteration in proteome of U251 gliomaspheres treated with tachyplesin I. A total of 192 differentially expressed proteins were identified, most of which are involved in the cellular process of metabolism, especially glycolysis process, and many proteins are localized as cytoskeleton proteins and lysosomal acid hydrolases. Especially, the expression level of some proteins of interest was validated by PRM, a high-resolution method first published in 2012 and had several potential advantages over traditional approach \[[@B21-marinedrugs-15-00020]\]. For example, PRM spectra are highly specific as a result of all the product ions of a peptide are recorded to confirm peptide identity, while traditional MRM analysis can only monitor one transition of a precursor peptide at a time. Moreover, high-resolution of the orbitrap mass analyzer can separate co-eluted background ions, thus increasing selectivity \[[@B22-marinedrugs-15-00020]\].

One of the hallmarks of tumor cells is the preference of glycolysis over oxidative phosphorylation as the main source of energy. Although glycolysis yield less ATP compared to oxidative phosphorylation with the same amount of beginning materials, tumor cells overcome this disadvantage by increasing the up-take of glucose, thus facilitates a higher rate of glycolysis \[[@B23-marinedrugs-15-00020]\]. Studies have showed that glycolysis plays a role in the invasion activity of glioma cells and is becoming a potential drug target \[[@B24-marinedrugs-15-00020]\]. In this study, glycolytic/gluconeogenesis enzymes including alpha-enolase (ENO1), gamma-enolase (ENO2), triosephosphate isomerase (TPI1) and phosphoglycerate kinase 1 (PGK1) were down-regulated in response to tachyplesin I treatment, indicating that tachyplesin I may disrupt the normal energy metabolism process in gliomaspheres through reduced glycolysis, thus contributing to its anti-tumor effect.

Uncontrolled and invasive proliferation is one feature of grade IV glioma, and in order to block and restrain mitotic division, cytoskeleton has been a time-honored target in cancer chemotherapy \[[@B25-marinedrugs-15-00020]\]. In this study, tachyplesin I treatment on U251 gliomaspheres altered the expression of 18 cytoskeleton proteins as classified by PANTHER classification system. Among them, vimentin and ezrin, which are known to be involved in the regulation of metastasis, were down-regulated under the treatment of tachyplesin I, suggesting that cytoskeleton are influenced by tachyplesin I, thus contributes to its anti-tumor activity.

Out of 192 altered proteins, 15 are lysosomal acid hydrolases, including proteases, glycosidases, sulfatases, lipases and so on. In addition, DAVID pathway classification system revealed lysosome as the most significantly altered pathway. More and more experimental evidences suggest that tumor invasion and metastasis are associated with alterations in lysosomes and increased expression of the lysosomal proteases termed cathepsins \[[@B26-marinedrugs-15-00020]\]. In this study, cathepsins consist of cathepsin A, B and D were down-regulated in response to tachyplesin I treatment. Cathepsin A, also called lysosomal protective protein, is a serine carboxypeptidase implicated in autophagy. It induces tumor cell dissemination and a significant increase in cathepsin A activity in lysates of metastatic lesions of malignant tumor was observed compared to primary focus lysates \[[@B27-marinedrugs-15-00020]\]. Cathepsin B is a lysosomal cysteine protease of the papain family of enzymes that function as an endopeptidase and an exopeptidase \[[@B28-marinedrugs-15-00020]\]. Cathepsin D, an aspartic protease resides in membrane of lysosomes, is involved in autophagy and apoptosis pathways \[[@B29-marinedrugs-15-00020]\]. Interestingly, it has been shown that cathepsin B and D play an important role in human glioma progression and invasion \[[@B30-marinedrugs-15-00020]\]. The expression and enzyme activity of cathepsin B and D gradually increased in high-grade glioblastoma. Inhibition of cathepsin B or D activity attenuates extracellular matrix degradation thus reduces migration of glioma cells \[[@B31-marinedrugs-15-00020]\]. Our data showed that the levels of these cathepsins were significantly decreased in tachyplesin I-treated gliomaspheres compared with untreated cells. All those evidences indicate the potential of tachyplesin I as a therapeutic agent for glioma by targeting the lysosomal activity.

In further PPI analysis of differentially expressed proteins, DNA topoisomerase 2-alpha (TOP2A) was shown to be the possible critical target protein of tachyplesin I. TOP2A is a nuclear enzyme for regulation of DNA topology and replication. TOP2A was discovered to be the target of many anti-tumor drugs which had already been widely used in clinic. Previous reports have shown that DNA damage and fragmentation induced by covalent binding of TOP2A to DNA, and forced expression of TOP2A in cells triggered the apoptotic cell death \[[@B32-marinedrugs-15-00020],[@B33-marinedrugs-15-00020]\]. In addition, the TOP2A level has a close relationship with the activity of these anti-tumor drugs and a high level of TOP2A is the foundation of drug susceptibility. Meanwhile, decreased level, altered phosphorylation or mutation of TOP2A could induce the loss of anti-tumor drug target and develop multiple drug resistance (MDR), which has been confirmed in atypical MDR studies with many cell lines \[[@B34-marinedrugs-15-00020],[@B35-marinedrugs-15-00020]\]. Our results showed that there was an increased TOP2A level in U251 gliomaspheres treated with tachyplesin I and it suggest the possible synergistic effect with TOP2A-targeting drugs, combination of which may be more effective on targeted goals and improve chemotherapy effect.

4. Material and Methods {#sec4-marinedrugs-15-00020}
=======================

4.1. Cell Culture and Treatment with Tachyplesin I {#sec4dot1-marinedrugs-15-00020}
--------------------------------------------------

U251 human glioma cells were obtained from the Chinese Academy of Sciences Cell Band (Shanghai, China) and cultured in RPMI-1640 medium containing 10% fetal bovine serum (FBS) and 100 units/mL penicillin/streptomycin at 37 °C in a humidified atmosphere with 5% CO~2~. The U251 cells in the logarithmic growth phase were thoroughly dissociated to prepare single-cell suspensions. Cell suspensions were washed twice in PBS and resuspended in Neurobasal-A medium with 1× B27 plus 50 ng/mL basic fibroblast growth factor (bFGF) and 50 ng/mL epidermal growth factor (EGF). After 7 days culture, clones of different morphological types were collected. The obtained cells which exhibited certain glioma stem cell phenotypes \[[@B11-marinedrugs-15-00020]\] were cultured as gliomaspheres and passaged every 7 days, based on sphere size.

Tachyplesin I was synthesized by Hanyu Bioengineering Company (Shenzhen, China) with a purity of \>95%. Concentrations of tachyplesin I for cell exposure were determined by cell viability assay as described previously \[[@B11-marinedrugs-15-00020]\]. The second generation gliomaspheres were treated with 0, 10, 40 and 80 μg/mL of tachyplesin I for 24 h, and then cells were centrifuged and collected.

4.2. CyDye Minimal Labeling of Protein Samples and 2D-DIGE Electrophoresis {#sec4dot2-marinedrugs-15-00020}
--------------------------------------------------------------------------

Proteins were extracted from gliomaspheres treated with 0, 10, 40 and 80 μg/mL of tachyplesin I using the lysis buffer containing 7 M urea, 2 M thiourea, 4% (*w*/*v*) CHAPS and 30 mM Tris-HCl. The concentrations of proteins were determined with the 2-D Quant kit (GE Healthcare, Piscataway, NJ, USA) according to the manufacturer's instructions. Then an equal amount (25 μg) of each protein sample was minimally labeled with Cy3 or Cy5 fluorescent dyes (GE Healthcare) according to the manufacturer's recommended protocols and the internal standard, resulting from pooling equal aliquots of all experimental samples, was labeled with Cy2.

Six differently pooled samples ([Table 4](#marinedrugs-15-00020-t004){ref-type="table"}), which comprised equal amounts of Cy3- and Cy5-labeled protein samples and Cy2-labeled internal standard, were then separated by first dimension of isoelectric focusing using 24 cm IPG strips (pH 3--11, nonlinear gradient, GE Healthcare), followed by second dimension separation into 12.5% SDS-PAGE gels. Gels were then scanned with different channels for Cy2-, Cy3-, and Cy5-labeled proteins, using a Typhoon Trio Variable Mode Imager (GE Healthcare). The resulting 18 maps were imported into DeCyder 2D v6.5 (GE Healthcare) for statistical analysis. Each gel was separately processed by the Differential In-gel Analysis (DIA) module for spot detection, background subtraction and in-gel normalization before processed by the Biological Variation Analysis (BVA) module for spot matching and intercomparison across the six gels. Student's *t*-test was used to analyze the significance of protein spots between two groups, and one way ANOVA was subsequently used to assess the biological significance among all the experimental groups. Statistically significant spots (*p* \< 0.05) with an average ratio ≥1.5 or ≤−1.5 were chosen for protein identification.

4.3. In-Gel Digestion and Protein Identification by MALDI-TOF/TOF {#sec4dot3-marinedrugs-15-00020}
-----------------------------------------------------------------

For identification of spots of interest, a gel was prepared by separating 1 mg of unlabeled proteins pooled from all the samples. The gel was stained by Coomassie Brilliant Blue G-250 and destained by water to reveal the protein spots. After matching to the analytical DIGE gel, each spot of interest was manually excised from the gel and put into a 1.5 mL tube, followed by thorough decoloration with 50% acetonitrile in 25 mM ammonium bicarbonate and dehydration in 100% acetonitrile. Then each gel piece was digested overnight at 37 °C by trypsin in 25 mM ammonium bicarbonate buffer. Peptides were extracted from each gel piece, desalted, and identified by an UltrafleXtreme MALDI-TOF/TOF mass spectrometer (Bruker Daltonics, Billerica, MA, USA) according to previously described \[[@B20-marinedrugs-15-00020]\].

4.4. Dimethyl Labeling of Protein Samples {#sec4dot4-marinedrugs-15-00020}
-----------------------------------------

Cells were lysed with a lysis buffer containing 4% SDS, 100 mM Tris, pH 8.0 and 1× protease inhibitor cocktail (Roche, Indianapolis, IN, USA). Protein concentrations were determined using a Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MS, USA). One milligram protein from each sample was reduced with 5 mM dithiothreitol, alkylated with 15 mM iodoacetamide, and precipitated by methanol and chloroform \[[@B36-marinedrugs-15-00020]\]. The resulting pellets were resuspended in lysis buffer containing 8 M urea, 0.1 M Tris-HCl, pH 8.5 and the concentration of urea was diluted to below 2 M before overnight digestion with trypsin (Promega, Madison, WI, USA).

Dimethyl labeling was performed on-column according to Nature Protocols by Boersema P.J. et al. \[[@B37-marinedrugs-15-00020]\] with minor modifications. Briefly, acidified peptide samples were loaded into SepPak columns (Waters, Milford, MA, USA) after the columns were activated by methanol, 80% acetonitrile in 0.1% trifluoroacetic acid (TFA), and conditioned by 0.1% TFA. After desalting, the samples were labeled separately by passing the columns with CH~2~O and NaBH~3~CN (light), CD~2~O and NaBH~3~CN (medium) and CD~2~O and NaBD~3~CN (heavy) (Sigma-Aldrich, St. Louis, MO, USA) for 20 min at room temperature. Labeling scheme was shown in [Table 5](#marinedrugs-15-00020-t005){ref-type="table"}. Then the differentially labeled samples were eluted from the columns, mixed and dried by Speedvac (Labconco, Kansas, MO, USA).

4.5. High pH Fractionation of Peptides and LC-MS/MS Analysis by Obitrap {#sec4dot5-marinedrugs-15-00020}
-----------------------------------------------------------------------

The dimethyl-labeled sample was resuspended in 1% formic acid (FA), loaded into SepPak column, and fractionated into five fractions by eluting the peptides with 3%, 6%, 9%, 15% and 80% (vol/vol) acetonitrile in 5 mM ammonium formate (pH 10.0), sequentially. After lyophilization in Speedvac, samples were resuspended in 0.1% FA and analyzed by a Q-Exactive orbitrap mass spectrometer (Thermo Fisher Scientific) coupled to an Easy-nLC 1000 (Thermo Fisher Scientific) ultrahigh pressure liquid chromatography (UHPLC). The LC separation system consisted of a trap column (100 μm i.d. × 4 cm) and an analytical column (75 μm i.d. × 20 cm) both packed with 3 μm/120 Å C18 resins (Dr. Maisch HPLC GmbH, Ammerbuch, Germany). The eluting buffers were 0.1% FA in H~2~O (buffer A) and 0.1% FA in 99.9% ACN (buffer B). The peptides were first loaded onto the trap column and then separated by the analytical column with 50 min gradient from 7% to 22% buffer B followed by 10 min gradient from 22% to 35% buffer B at a flow rate of 300 nL/min. MS data was acquired in data dependent acquisition (DDA) mode. Survey full scan MS spectra (*m*/*z* 350--1550) were acquired in the Orbitrap with resolution of 70,000, target automatic gain control (AGC) value of 3 × 10^6^, and maximum injection time of 100 ms. Dynamic exclusion for scanned presursors was employed for 60 s. After each MS scan, the 10 most intense precursor ions (*z* ≥ 2) were sequentially isolated and fragmented by higher-energy collisional dissociation (HCD) using normalized energy 27% with an AGC target of 1 × 10^5^ and a maxima injection time of 50 ms at 17,500 resolution.

Raw data were searched through UniProt Homo sapiens protein database containing 70,076 sequence entries via Sequest HT algorithm with the following parameters: two missed cleavage sites by trypsin, 10 ppm mass tolerance for precursors, 0.02 Da mass tolerance for fragments, and carbamidomethylation (+57.021 Da) of cysteineas static modifications. Moreover, the following dynamic modifications were also set: oxidation of methionine (+15.995 Da), deamidation of asparagine or glutarnine (+0.984 Da), and dimethylation for light-labeled (+28.031 Da) or medium-labeled (+32.056 Da) or heavy-labeled (+36.076 Da) lysine, and *N*-terminus. All the identified peptides were filtered by FDR \<0.01 as reliable identification. Protein Discoverer was used for relative quantification. Differentially expressed proteins were considered for ratios ≤0.5 (down-regulated) and ≥2 (up-regulated).

4.6. Bioinformatic Analysis {#sec4dot6-marinedrugs-15-00020}
---------------------------

The function reports of the candidate proteins whose expression was altered in U251 gliomaspheres due to the effect of tachyplesin I treatment were obtained from the UniProt database (<http://www.uniprot.org/>) and the protein list of UniProt IDs was input into the PANTHER classification system (<http://pantherdb.org/>) for GO analysis according to their molecular functions and biological processes. The relevant signaling pathways highly associated with the effect of tachyplesin I treatment on U251 gliomaspheres were identified using DAVID analysis (<https://david.ncifcrf.gov/>). The protein--protein interaction network of all the differentially expressed proteins was established using String (<http://string-db.org/>), and then the data was exported as .net file and imported into pajek software for degree based partition of the proteins in the network. The correlation of the possible key proteins involved in the effects of tachyplesin I in our proteomic analysis with its mRNA transcript level and clinical prognosis in GBM patients based on per TCGA data was analyzed by cBioPortal tools (<http://www.cbioportal.org/>) \[[@B38-marinedrugs-15-00020]\].

4.7. Parallel Reaction Monitoring (PRM) Mass Spectrometry {#sec4dot7-marinedrugs-15-00020}
---------------------------------------------------------

We applied PRM to validate the major protein changes observed in the dimethyl labeling analyses. Proteins were extracted from another batch of differently treated U251 gliomaspheres (biological replicate) and digested to peptides. These unlabeled peptides were fractionated and identified as described above with only difference in database searching (no dimethylation as dynamic modifications). For PRM analysis, 2 μg of non-fractionated peptides from each group were separated using the same LC system. Linear gradient ranging from 4% to 35% buffer B over 60 min was used. For each target protein, two unique precursor peptide ions were monitored in the inclusion list. The settings for MS full scan were the same as in the DDA mode with only different in *m*/*z* scan range (300--900). The following MS/MS PRM scan parameters were set: orbitrap resolution of 35,000, AGC target value of 5 × 10^5^, auto maximum IT, isolation window of 2 *m*/*z*, HCD collision energy of 27, and starting mass of *m*/*z* 110. The PRM raw files were analysed using Skyline \[[@B39-marinedrugs-15-00020]\] to extract the peak areas of six to seven most intense transitions for each peptide. Then the data was imported to GraphPad for statistical analysis. Differences between two groups were analyzed by the Student's *t*-test and statistical significance was considered when *p* \< 0.05.

4.8. Western Blot Assay {#sec4dot8-marinedrugs-15-00020}
-----------------------

Total proteins were extracted from different groups of U251 gliomaspheres with the same treatment as described in the DIGE analysis, and protein concentrations were quantified by BCA kit. Western blot procedures were carried out as we previously described \[[@B40-marinedrugs-15-00020]\], with minor modifications. Namely, after boiling for 5 min with loading buffer, the same amount of proteins from each groups were separated by SDS-PAGE and transferred onto PVDF membranes. The membranes were incubated with mouse monoclonal anti-ECE-1 antibody (sc-376017, Santa Cruz, CA, USA), mouse monoclonal anti-alpha-enolase (sc-101513, Santa Cruz, CA, USA), mouse monoclonal anti-cathepsin A (sc-73766, Santa Cruz, CA, USA) and mouse monoclonal anti-GAPDH (sc-32233, Santa Cruz, CA, USA) at 1:500 dilution. The immunoblots were developed by incubation with goat anti-mouse IgG-HRP (sc-2005, Santa Cruz, CA, USA) as the secondary antibody followed by ECL detection (GE Healthcare).

5. Conclusions {#sec5-marinedrugs-15-00020}
==============

In our study, we combined a gel-based 2D-DIGE approach and a dimethyl labeling LC-MS-based shotgun proteomic strategy to identify the proteome expression alterations in U251 gliomaspheres treated with different doses of tachyplesin I. Our results demonstrate complementary advantages of these two techniques. We show that tachyplesin I alters the cellular metabolism, especially glycolysis process and changes the expression of several cytoskeleton proteins and lysosomal acid hydrolases. Moreover, the important role of DNA topoisomerase 2-alpha (TOP2A) in the signal cascades of tachyplesin I was suggested. Further, parallel reaction monitoring (PRM) mass spectrometry confirmed that the major protein of lysosomal acid hydrolases including cathepsin A, cathepsin B and cathepsin D were down-regulated and the possible target-related protein TOP2A was up-regulated by tachyplesin I treatment. In conclusion, we propose that tachyplesin I may down-regulate cathepsins in lysome and up-regulate TOP2A to inhibit migration and promote apoptosis in glioma, thus contributing to its anti-tumor activity. Further work including functional analyses is needed to elucidate the mode of action of tachyplesin I in tumor cells. As far as we know, there is no previous report that reveals the effect of tachyplesin I on proteome of gliomaspheres and our findings imply that tachyplesin I could serve as a promising candidate in the combined therapy against glioma.
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![Two dimension difference gel electrophoresis (2D-DIGE) analysis of U251 gliomaspheres after treated with tachyplesin I. (**A**) Representative scanned 2D-DIGE images of Cy2, Cy3, and Cy5, and their overlay derived from a single gel; (**B**) Representative 2D-DIGE protein profiles with the protein spots marked as differentially regulated in U251 gliomaspheres treated with tachyplesin I. Information about the proteins corresponding to the spot numbers is listed in [Table 1](#marinedrugs-15-00020-t001){ref-type="table"}; (**C**) The expression levels of endothelin-converting enzyme 1 (ECE1) and alpha-enolase (ENO1) in U251 gliomaspheres treated by 0, 10, 40 and 80 μg/mL of tachyplesin I for 24 h are visualized by protein abundance maps (first panel), 2-DE images (second panel), three-dimensional spot images (third panel) and validated by Western blot (bottom panel). GAPDH was used as a loading control.](marinedrugs-15-00020-g001){#marinedrugs-15-00020-f001}
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Dimethyl labeling based Liquid chromatography--mass spectrometry/mass spectrometry (LC-MS/MS) analysis of U251 gliomaspheres after treated with tachyplesin I. (**A**) Distribution of quantified protein log~2~ ratios; (**B**) A Venn diagram shows the number of proteins identified in either forward or reverse labeling experiment, as well as the overlap between them; (**C**) A scatter plot showing the forward (*y*-axis) and reverse (*x*-axis) dimethyl labeling log~2~ ratios for the 4008 proteins that were identified and quantified in both experiment, the left panel corresponds to 10 μg/mL group versus control, the right panel corresponds to 40 μg/mL group versus control. The values for each protein are shown as a blue diamond; (**D**) Representative mass spectrometric image revealing the tachyplesin I-induced down regulation of cathepsin D. Shown are the MS for the peptide DPDAQPGGELMLGGTDSK of cathepsin D from the forward (left panel) and reverse (right panel) dimethyl labeling samples.
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![Gene ontology analysis of 192 differentially expressed proteins. The significant (*p* ≤ 0.001) molecular functions (**A**) and biological processes (**B**) are presented in the pie chart.](marinedrugs-15-00020-g003){#marinedrugs-15-00020-f003}

![Tachyplesin I reduces expressions of several lysosomal acid hydrolases in U251 gliomaspheres. (**A**) Expression of cathepsin A (CTSA) was validated by Western blot. GAPDH was used as a loading control; (**B**) Expressions of CTSA, cathepsin B (CTSB) and cathepsin D (CTSD) were validated by PRM mass spectrometry. The quantification for two peptides per protein in different dose groups is presented.](marinedrugs-15-00020-g004){#marinedrugs-15-00020-f004}

![Role of DNA topoisomerase 2-alpha (TOP2A) in protein--protein interaction (PPI) map of tachyplesin I. (**A**) The constructed minimum PPI network of tachyplesin I containing 192 differentially expressed proteins found in 2D-DIGE and dimethyl labeling-based LC-MS analysis; (**B**) Degree distribution map of the proteins in PPI network of tachyplesin I. The proteins are shown as round dots and different colors were only related to degree in the network. TOP2A exhibited to have the biggest degree among all differentially expressed proteins; (**C**) Expression of TOP2A was validated by Western blot. GAPDH was used as a loading control; (**D**) Expression of TOP2A was validated by PRM mass spectrometry. The quantification for two peptides per protein in different dose groups is presented; (**E**) The overall survival (left panel) and the disease-free survival (right panel) of glioma cases with or without alterations in TOP2A. The red curves in the Kaplan--Meier plots includes cases with alterations in TOP2A, the blue curves includes cases without alterations in TOP2A.](marinedrugs-15-00020-g005){#marinedrugs-15-00020-f005}
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Regulated proteins of tachyplesin I treated U251 gliomaspheres in the 2D-DIGE study.

  Up-Regulated Proteins of Tachyplesin I Treated U251 Gliomaspheres in the 2D-DIGE Study                                                                                                                              
  ---------------------------------------------------------------------------------------------- ---------- -------- ------------------------------------------------------- ----- ---- --------- ----- ------------- -------------
  Regulation of cell cycle or apoptosis ^d^                                                                                                                                                                           
  2                                                                                              PHGDH      O43175   [d]{.smallcaps}-3-phosphoglycerate dehydrogenase        104   3    57,356    6.3   1.54/0.003    1.69/0.017
  5                                                                                              MSH2       P43246   DNA mismatch repair protein Msh2                        93    2    104,743   5.8   1.21/0.009    1.77/0.035
  19                                                                                             SESN3      P58005   Sestrin-3                                               201   4    57,291    6.3   1.52/0.036    2.01/0.027
  31                                                                                             CKAP2      Q8WWK9   Cytoskeleton-associated protein 2                       76    7    76,987    9.4   ND ^e^        1.52/0.039
  35                                                                                             ECE1       P42892   Endothelin-converting enzyme 1                          46    1    87,164    5.9   1.58/0.038    3.31/0.026
  Cytoskeletal protein ^d^                                                                                                                                                                                            
  3                                                                                              VIM        P08670   Vimentin                                                407   12   53,676    4.9   ND            1.64/0.022
  4                                                                                              EEF1G      P26641   Elongation factor 1-gamma                               47    2    50,429    6.3   ND            1.51/0.005
  9                                                                                              EZR        P15311   Ezrin                                                   168   3    69,484    5.9   1.03/0.024    1.63/0.046
  10                                                                                             VIM        P08670   Vimentin                                                524   15   53,676    4.9   ND            1.58/0.041
  Protein biosynthesis ^d^                                                                                                                                                                                            
  6                                                                                              EEF2       P13639   Elongation factor 2                                     60    1    96,246    6.4   ND            1.55/0.044
  21                                                                                             PPIA       P62937   Peptidyl-prolyl *cis*-*trans* isomerase A               195   16   18,229    9     1.26/0.017    1.52/0.028
  Transport ^d^                                                                                                                                                                                                       
  23                                                                                             SLC25A3    F8VVM2   Phosphate carrier protein, mitochondrial                90    5    36,161    9.3   ND            1.72/0.034
  25                                                                                             SLC25A3    F8VVM2   Phosphate carrier protein, mitochondrial                183   9    36,161    9.3   ND            1.63/0.016
  **Down-Regulated Proteins of Tachyplesin I Treated U251 Gliomaspheres in the 2D-DIGE Study**                                                                                                                        
  Calcium or iron ion binding protein ^d^                                                                                                                                                                             
  7                                                                                              EPS15      P42566   Epidermal growth factor receptor substrate 15           109   5    98,656    5.1   ND ^e^        −1.88/0.004
  13                                                                                             P4HA1      P13674   Prolyl 4-hydroxylase subunit alpha-1                    86    5    61,296    5.6   −1.51/0.007   −2.37/0.045
  Regulation of cell apoptosis or proliferation ^d^                                                                                                                                                                   
  12                                                                                             ANXA5      P08758   Annexin A5                                              273   13   35,971    4.8   ND            −1.74/0.033
  20                                                                                             GSTP1      P09211   Glutathione *S*-transferase P                           339   21   23,569    5.3   ND            −1.66/0.001
  33                                                                                             COL4A3BP   Q9Y5P4   Collagen type IV alpha-3-binding protein                250   7    70,835    5.5   ND            −1.64/0.033
  34                                                                                             ARHGDIA    P52565   Rho GDP-dissociation inhibitor 1                        236   16   23,250    4.9   −1.23/0.037   −2.64/0.047
  Response to stimulus ^d^                                                                                                                                                                                            
  14                                                                                             GNAQ       P50148   Guanine nucleotide-binding protein G(q) subunit alpha   193   9    42,142    5.7   ND            −1.61/0.037
  16                                                                                             GNAQ       P50148   Guanine nucleotide-binding protein G(q) subunit alpha   294   12   42,142    5.7   ND            −1.59/0.047
  28                                                                                             GNAQ       P50148   Guanine nucleotide-binding protein G(q) subunit alpha   182   7    42,142    5.7   −1.33/0.028   −1.53/0.036
  Glycolysis/Gluconeogenesis ^d^                                                                                                                                                                                      
  15                                                                                             ENO1       P06733   Alpha-enolase                                           40    3    47,481    7.7   −1.04/0.005   −1.92/0.054
  17                                                                                             PGK1       P00558   Phosphoglycerate kinase 1                               209   7    44,985    9.2   −1.68/0.025   −2.89/0.051
  30                                                                                             TPI1       P60174   Triosephosphate isomerase                               375   15   31,057    5.6   −1.17/0.048   −1.88/0.028
  Ribosomal protein ^d^                                                                                                                                                                                               
  18                                                                                             RPSA       P08865   40S ribosomal protein SA                                171   9    32,947    4.6   −1.49/0.036   −1.89/0.027

^a^ No.---The numbers correspond to the spot numbers indicated in [Figure 1](#marinedrugs-15-00020-f001){ref-type="fig"}B; ^b^ Average ratios of spot abundance of tachyplesin I-treated samples relative to the control, represent data from three separate experiments and student's *t* test *p* values are given as a measure of confidence for the ratio of each spot measured; ^c^ 0: control group; 10: 10 μg/mL dose group; 40: 40 μg/mL dose group; ^d^ Functional categories according to Gene ontology and panther biological process annotations; ^e^ ND, not detected or *p* value \> 0.5.
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List of proteins with altered expression in U251 gliomaspheres after treatment of tachyplesin I using dimethyl labeling quantitative proteomic analysis.

  The 55 Up-Regulated Proteins Expressed More Than 2 Folds (\<1% FDR)                                                                                                                                              
  ------------------------------------------------------------------------------ ------------ -------------------------------------------------------------------- ------- ----- ------- ------- -------- -------- ----------------------------------------------------------
  SPP1                                                                           P10451       Osteopontin                                                          33.12   5     4.961   2.943   12.876   9.484    cytokine
  ITGB3                                                                          P05106       Integrin beta-3                                                      5.20    3     4.754   5.953   13.279   28.714   receptor, extracellular matrix glycoprotein
  EPS8                                                                           Q12929       Epidermal growth factor receptor kinase substrate 8                  4.01    3     4.403   2.549   2.220    2.305    transmembrane receptor regulatory/adaptor protein
  MCM5                                                                           B1AHB1       DNA helicase                                                         5.50    3     3.304   2.022   3.801    2.194    DNA helicase
  DKK1                                                                           O94907       Dickkopf-related protein 1                                           11.28   4     3.267   2.278   3.885    2.732    developmental protein, growth factor activity
  MCM4                                                                           P33991       DNA replication licensing factor MCM4                                7.76    4     3.248   2.119   5.189    3.723    DNA binding protein
  NUSAP1                                                                         Q9BXS6       Nucleolar and spindle-associated protein 1                           18.14   5     2.661   2.293   3.121    3.405    microtubule-associated protein
  DHFR                                                                           P00374       Dihydrofolate reductase                                              24.06   4     2.616   2.168   2.398    2.472    reductase
  TOP2A                                                                          P11388       DNA topoisomerase 2-alpha                                            12.93   12    2.490   2.916   3.259    2.582    DNA topoisomerase, enzyme modulator
  MKI67                                                                          A0A087WV66   Antigen KI-67                                                        12.66   24    2.396   1.870   2.688    2.047    regulation of cell proliferation
  TFRC                                                                           P02786       Transferrin receptor protein 1                                       35.79   23    2.323   2.398   2.906    2.879    receptor
  AIM1                                                                           Q9Y4K1       Absent in melanoma 1 protein                                         21.53   25    2.298   2.329   4.036    5.403    carbohydrate binding protein
  ECE1                                                                           P42892       Endothelin-converting enzyme 1                                       15.19   8     2.260   2.671   3.557    4.070    metalloprotease
  SYNJ2                                                                          O15056       Synaptojanin-2                                                       8.76    11    2.239   2.501   5.349    4.740    phosphatase
  KIF11                                                                          P52732       Kinesin-like protein KIF11                                           2.37    2     2.199   2.274   2.469    2.182    microtubule binding motor protein
  DST                                                                            Q03001       Dystonin                                                             23.49   21    2.113   1.596   2.614    2.051    non-motor actin binding protein
  UPP1                                                                           Q16831       Uridine phosphorylase 1                                              46.45   11    2.078   2.712   2.209    3.577    phosphorylase
  IGFBP5                                                                         P24593       Insulin-like growth factor-binding protein 5                         20.59   5     2.070   2.060   4.816    4.967    cell communication
  RRM2                                                                           P31350       Ribonucleoside-diphosphate reductase subunit M2                      34.45   11    2.030   1.981   2.286    2.423    reductase
  CD70                                                                           P32970       CD70 antigen                                                         35.23   6     1.995   2.167   3.725    3.808    cell communication
  MDK                                                                            E9PPJ5       Midkine (Fragment)                                                   27.48   2     1.935   2.538   3.569    4.336    cytokine
  HMGCS1                                                                         Q01581       Hydroxymethylglutaryl-CoA synthase, cytoplasmic                      42.88   17    1.929   1.939   3.322    4.339    transferase, lyase
  DCLK1                                                                          Q5VZY9       Serine/threonine-protein kinase DCLK1                                10.74   3     1.899   3.222   4.721    8.819    non-receptor serine/threonine protein kinase
  MCM7                                                                           P33993       DNA replication licensing factor MCM7                                13.21   7     1.879   1.963   2.451    2.470    DNA helicase
  PODXL                                                                          O00592       Podocalyxin                                                          2.33    1     1.870   2.234   2.474    2.856    regulation of adhesion and cell morphology
  MCM2                                                                           H0Y8E6       DNA replication licensing factor MCM2 (Fragment)                     8.25    6     1.865   1.513   2.167    2.664    DNA helicase
  LPL                                                                            P06858       Lipoprotein lipase                                                   34.11   12    1.848   2.078   4.136    4.351    storage protein
  VSNL1                                                                          P62760       Visinin-like protein 1                                               24.08   4     1.805   2.260   3.231    2.926    cell communication
  MCM6                                                                           Q14566       DNA replication licensing factor MCM6                                9.01    4     1.765   2.208   2.606    3.031    DNA helicase
  GPC1                                                                           P35052       Glypican-1                                                           33.69   14    1.745   1.665   2.861    3.347    cell division and growth regulation
  TACC3                                                                          Q9Y6A5       Transforming acidic coiled-coil-containing protein 3                 3.22    2     1.735   2.068   2.563    2.322    cytoskeleton
  TNC                                                                            P24821       Tenascin                                                             40.16   5     1.730   1.803   2.327    2.112    signaling molecule
  PLAT                                                                           P00750       Tissue-type plasminogen activator                                    24.73   12    1.729   3.475   8.267    13.172   receptor, calmodulin
  GATM                                                                           P50440       Glycine amidinotransferase, mitochondrial                            28.61   9     1.704   1.793   2.591    2.740    catalyze creatine biosynthesis
  SERPINE1                                                                       P05121       Plasminogen activator inhibitor 1                                    21.14   7     1.695   1.448   4.539    3.853    serine protease inhibitor
  LMCD1                                                                          Q9NZU5       LIM and cysteine-rich domains protein 1                              38.63   10    1.681   1.686   2.388    2.243    structural protein
  TYMS                                                                           P04818       Thymidylate synthase                                                 19.17   4     1.675   2.752   2.151    3.228    methyltransferase
  ITGA3                                                                          P26006       Integrin alpha-3                                                     21.41   19    1.671   1.729   2.847    2.944    receptor, integrin
  ANLN                                                                           Q9NQW6       Actin-binding protein anillin                                        3.91    3     1.666   2.235   2.308    3.143    actin binding protein
  ANXA2                                                                          P07355       Annexin A2                                                           81.42   34    1.617   1.610   2.023    2.100    fatty acid metabolic process
  MACF1                                                                          H3BPE1       Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5           29.64   153   1.610   1.601   2.018    2.000    non-motor actin binding protein
  TPM4                                                                           P67936       Tropomyosin alpha-4 chain                                            48.79   8     1.534   2.126   2.878    2.893    actin binding motor protein
  ACTN4                                                                          K7EJH8       Alpha-actinin-4 (Fragment)                                           68.68   1     1.526   2.411   2.251    3.153    non-motor actin binding protein
  TRIM9                                                                          Q9C026       E3 ubiquitin-protein ligase TRIM9                                    4.23    3     1.508   1.143   2.077    2.109    ubiquitin-protein ligase
  LDLR                                                                           P01130       Low-density lipoprotein receptor                                     6.63    5     1.498   1.202   2.266    2.096    receptor, extracellular matrix glycoprotein
  SDCBP                                                                          O00560       Syntenin-1                                                           28.52   4     1.495   1.490   2.581    3.361    membrane trafficking regulatory protein
  TF                                                                             P02787       Serotransferrin                                                      45.13   27    1.422   1.526   2.224    2.216    transfer/carrier protein
  TENM2                                                                          H7BYZ1       Teneurin-2                                                           13.86   24    1.422   1.735   2.046    2.501    receptor, membrane-bound signaling molecule
  NES                                                                            P48681       Nestin                                                               58.61   78    1.396   1.363   2.140    2.167    structural protein
  THY1                                                                           E9PIM6       Thy-1 membrane glycoprotein (Fragment)                               25.66   3     1.360   1.468   2.432    2.131    membrane glycoprotein
  NEFL                                                                           P07196       Neurofilament light polypeptide                                      47.88   28    1.213   1.182   2.121    2.010    structural protein
  CLSTN1                                                                         Q5SR54       Calsyntenin-1 (Fragment)                                             4.35    3     1.181   1.201   2.338    2.552    cell adhesion molecule, calcium-binding protein
  ECI2                                                                           A0A0C4DGA2   Enoyl-CoA delta isomerase 2, mitochondrial                           40.38   11    1.148   1.262   2.239    2.894    transfer/carrier protein, enzyme modulator
  PTPRE                                                                          P23469       Receptor-type tyrosine-protein phosphatase epsilon                   11.29   5     0.939   2.069   3.282    3.385    receptor, protein phosphatase
  LRRC16A                                                                        Q5VZK9       Leucine-rich repeat-containing protein 16A                           1.90    2     ND      1.408   2.281    3.321    transcription cofactor
  **The 111 Down-Regulated Proteins Expressed Less Than 0.5 Folds (\<1% FDR)**                                                                                                                                     
  OASL                                                                           Q15646       2′-5′-oligoadenylate synthase-like protein                           12.26   4     0.127   0.393   0.215    ND       nucleotidyltransferase, defense/immunity protein
  OAS2                                                                           P29728       2′-5′-oligoadenylate synthase 2                                      9.74    9     0.151   0.158   0.115    0.068    nucleotidyltransferase, defense/immunity protein
  MX1                                                                            P20591       Interferon-induced GTP-binding protein Mx1                           56.50   28    0.164   0.177   0.150    0.130    microtubule family cytoskeletal protein
  IFI44L                                                                         Q53G44       Interferon-induced protein 44-like                                   39.60   13    0.179   0.206   0.189    0.191    immune response
  IFI44                                                                          Q8TCB0       Interferon-induced protein 44                                        33.56   13    0.193   0.231   0.158    0.181    immune response
  CASP1                                                                          G3V169       Caspase                                                              19.35   4     0.209   0.325   0.235    0.180    regulation of apoptotic process
  BTN3A2                                                                         E9PRR1       Butyrophilin subfamily 3 member A2 (Fragment)                        27.55   2     0.220   0.555   0.261    0.360    ubiquitin-protein ligase
  INS                                                                            C9JNR5       Insulin (Fragment)                                                   7.61    1     0.228   0.231   0.634    0.769    growth factor
  MX2                                                                            P20592       Interferon-induced GTP-binding protein Mx2                           16.05   5     0.235   0.140   0.129    0.215    microtubule family cytoskeletal protein
  PARP10                                                                         E9PPE7       Poly \[ADP-ribose\] polymerase 10                                    4.71    2     0.260   0.280   0.201    0.508    nucleic acid binding
  ISG15                                                                          A0A096LNZ9   Ubiquitin-like protein ISG15 (Fragment)                              50.35   6     0.273   0.293   0.253    0.264    ribosomal protein
  TAP1                                                                           Q03518       Antigen peptide transporter 1                                        29.08   15    0.287   0.385   0.288    0.288    ATP-binding cassette (ABC) transporter
  IFIT3                                                                          O14879       Interferon-induced protein with tetratricopeptide repeats 3          48.57   18    0.288   0.301   0.261    0.258    RNA binding
  IFIT2                                                                          P09913       Interferon-induced protein with tetratricopeptide repeats 2          30.08   11    0.294   0.291   0.212    0.250    RNA binding
  IFIT1                                                                          P09914       Interferon-induced protein with tetratricopeptide repeats 1          45.82   16    0.300   0.321   0.296    0.301    RNA binding
  KRT10                                                                          P13645       Keratin, type I cytoskeletal 10                                      30.14   13    0.301   0.314   0.483    0.541    structural protein
  DDX58                                                                          O95786       Probable ATP-dependent RNA helicase DDX58                            41.73   37    0.307   0.307   0.278    0.265    helicase, hydrolase
  BLOC1S1                                                                        G8JLQ3       Biogenesis of lysosome-related organelles complex 1 subunit 1        50.67   3     0.308   0.461   0.296    0.417    transcription factor
  TRIM21                                                                         P19474       E3 ubiquitin-protein ligase TRIM21                                   7.79    3     0.310   0.382   0.259    0.340    ubiquitin-protein ligase
  OAS3                                                                           Q9Y6K5       2′-5′-oligoadenylate synthase 3                                      30.08   29    0.316   0.306   0.246    0.237    nucleotidyltransferase, defense/immunity protein
  SLC4A4                                                                         Q9Y6R1       Electrogenic sodium bicarbonate cotransporter 1                      9.64    8     0.323   0.290   0.164    0.214    transporter
  TAPBP                                                                          O15533       Tapasin                                                              25.00   7     0.324   0.397   0.318    0.333    immunoglobulin receptor superfamily
  KRT1                                                                           P04264       Keratin, type II cytoskeletal 1                                      36.49   18    0.325   0.273   0.550    0.447    structural protein
  DTX3L                                                                          Q8TDB6       E3 ubiquitin-protein ligase DTX3L                                    25.81   12    0.326   0.426   0.375    0.377    ubiquitin-protein ligase
  TAP2                                                                           Q03519       Antigen peptide transporter 2                                        22.16   10    0.350   0.350   0.280    0.270    ATP-binding cassette (ABC) transporter
  GBP1                                                                           P32455       Interferon-induced guanylate-binding protein 1                       28.38   13    0.362   0.346   0.296    0.202    heterotrimeric G-protein
  KRT9                                                                           P35527       Keratin, type I cytoskeletal 9                                       35.47   15    0.363   0.409   0.632    0.759    structural protein
  AGTRAP                                                                         Q6RW13       Type-1 angiotensin II receptor-associated protein                    13.84   1     0.383   0.479   0.557    0.604    response to hypoxia
  PARP9                                                                          Q8IXQ6       Poly \[ADP-ribose\] polymerase 9                                     16.28   12    0.387   0.392   0.395    0.359    nucleic acid binding
  HLA-B                                                                          P30466       HLA class I histocompatibility antigen, B-18 alpha chain             57.73   1     0.396   0.414   0.307    0.344    immunoglobulin receptor superfamily
  IRF9                                                                           Q00978       Interferon regulatory factor 9                                       7.38    3     0.405   0.588   0.318    0.377    immune response
  C19orf66                                                                       Q9NUL5       UPF0515 protein C19orf66                                             16.15   3     0.405   0.480   0.214    0.395    no function identified yet
  NT5E                                                                           P21589       5′-nucleotidase                                                      48.08   25    0.408   0.428   0.353    0.361    nucleotide phosphatase
  STAT1                                                                          P42224       Signal transducer and activator of transcription 1-alpha/beta        53.33   36    0.408   0.422   0.369    0.381    transcription factor, nucleic acid binding
  KRT2                                                                           P35908       Keratin, type II cytoskeletal 2 epidermal                            7.82    3     0.411   0.329   0.428    0.471    structural protein
  SP100                                                                          P23497       Nuclear autoantigen Sp-100                                           9.56    6     0.412   0.438   0.352    0.363    HMG box transcription factor, signaling molecule
  B2M                                                                            P61769       Beta-2-microglobulin                                                 37.82   4     0.419   0.413   0.369    0.332    major histocompatibility complex antigen
  ALB                                                                            A0A0C4DGB6   Serum albumin                                                        16.89   9     0.427   0.455   0.668    0.654    transfer/carrier protein
  BANF1                                                                          O75531       Barrier-to-autointegration factor                                    34.83   2     0.429   0.467   0.308    0.408    DNA binding, DNA integration
  IFIT5                                                                          Q13325       Interferon-induced protein with tetratricopeptide repeats 5          19.71   7     0.438   0.497   0.477    0.435    RNA-binding
  ERAP2                                                                          Q6P179       Endoplasmic reticulum aminopeptidase 2                               6.25    5     0.461   0.527   0.371    0.457    metalloprotease
  HLA-A                                                                          P01892       HLA class I histocompatibility antigen, A-2 alpha chain              64.38   15    0.465   0.509   0.415    0.447    immunoglobulin receptor superfamily
  NDRG1                                                                          Q92597       Protein NDRG1                                                        27.41   6     0.468   0.541   0.260    0.246    stress-responsive protein
  STAT2                                                                          P52630       Signal transducer and activator of transcription 2                   10.93   5     0.478   0.617   0.347    0.442    transcription factor, nucleic acid binding
  HLA-E                                                                          P13747       HLA class I histocompatibility antigen, alpha chain E                24.02   2     0.479   0.319   0.472    0.433    immunoglobulin receptor superfamily
  ATP6V0C                                                                        P27449       V-type proton ATPase 16 kDa proteolipid subunit                      11.61   1     0.484   0.353   0.906    0.805    hydrolase, ATP synthase
  UCHL3                                                                          P15374       Ubiquitin carboxyl-terminal hydrolase isozyme L3                     15.65   2     0.492   0.459   0.558    0.220    cysteine protease
  EPN2                                                                           F6PQP6       Epsin-2 (Fragment)                                                   19.56   7     0.496   0.576   0.262    0.295    endocytosis
  DBI                                                                            P07108       Acyl-CoA-binding protein                                             65.52   6     0.501   0.502   0.263    0.148    transfer/carrier protein
  SP110                                                                          G5E9C0       SP110 nuclear body protein, isoform CRA_b                            5.48    2     0.506   0.473   0.464    0.439    HMG box transcription factor, signaling molecule
  TCEAL3                                                                         Q969E4       Transcription elongation factor A protein-like 3                     16.50   2     0.507   0.478   0.354    0.307    transcription factor
  LGALS3BP                                                                       Q08380       Galectin-3-binding protein                                           39.83   19    0.507   0.533   0.427    0.457    receptor, serine protease
  UBE2L6                                                                         O14933       Ubiquitin/ISG15-conjugating enzyme E2 L6                             59.48   5     0.517   0.407   0.382    0.317    ligase
  SMYD2                                                                          Q9NRG4       *N*-lysine methyltransferase SMYD2                                   7.39    3     0.519   0.669   0.327    0.243    transcription cofactor
  TREX1                                                                          Q9NSU2       Three-prime repair exonuclease 1                                     7.86    2     0.526   0.463   0.482    0.389    catalytic activityi
  AK4                                                                            P27144       Adenylate kinase 4, mitochondrial                                    49.33   8     0.529   0.500   0.381    0.422    nucleotide kinase
  FAM96B                                                                         J3KS95       Mitotic spindle-associated MMXD complex subunit MIP18 (Fragment)     23.58   2     0.539   0.421   0.452    0.473    iron-sulfur cluster assembly
  DPP7                                                                           Q9UHL4       Dipeptidyl peptidase 2                                               35.37   12    0.541   0.581   0.365    0.431    serine protease
  PML                                                                            P29590       Protein PML                                                          33.79   22    0.545   0.558   0.424    0.392    activator
  AGA                                                                            P20933       N(4)-(beta-*N*-acetylglucosaminyl)-[l]{.smallcaps}-asparaginase      24.86   5     0.551   0.635   0.415    0.490    protease
  EPHA2                                                                          P29317       Ephrin type-A receptor 2                                             19.67   15    0.555   0.523   0.386    0.395    nervous system development
  SERPINI1                                                                       Q99574       Neuroserpin                                                          8.78    3     0.564   0.757   0.257    0.217    serine protease inhibitor
  PAPSS2                                                                         O95340       Bifunctional 3′-phosphoadenosine 5′-phosphosulfate synthase 2        37.30   18    0.567   0.544   0.336    0.276    nucleotidyltransferase
  IDUA                                                                           P35475       Alpha-[l]{.smallcaps}-iduronidase                                    31.85   16    0.572   0.605   0.416    0.479    glycosidase
  GLA                                                                            P06280       Alpha-galactosidase A                                                25.64   8     0.574   0.625   0.464    0.435    glycosidase, hydrolase
  SGSH                                                                           P51688       *N*-sulphoglucosamine sulphohydrolase                                29.68   11    0.578   0.515   0.353    0.410    hydrolase
  GAA                                                                            P10253       Lysosomal alpha-glucosidase                                          24.37   19    0.584   0.657   0.426    0.461    glucosidase
  CHSY3                                                                          Q70JA7       Chondroitin sulfate synthase 3                                       6.92    6     0.587   0.483   0.361    0.320    glycosyltransferase
  ACP5                                                                           K7EIP0       Tartrate-resistant acid phosphatase type 5 (Fragment)                36.54   1     0.587   0.544   0.313    0.246    glycosylated monomeric metalloprotein enzyme
  PSMB8                                                                          P28062       Proteasome subunit beta type-8                                       39.13   8     0.590   0.552   0.455    0.493    endopeptidase activity
  SPTBN2                                                                         O15020       Spectrin beta chain, non-erythrocytic 2                              4.35    2     0.593   0.738   0.389    0.358    non-motor actin binding protein
  PGM2L1                                                                         Q6PCE3       Glucose 1,6-bisphosphate synthase                                    48.07   30    0.598   0.627   0.492    0.448    glycosyltransferase, mutase
  SAMD9L                                                                         Q8IVG5       Sterile alpha motif domain-containing protein 9-like                 4.67    6     0.611   0.547   0.489    0.416    regulation of protein catabolic process
  CSTB                                                                           P04080       Cystatin-B                                                           45.92   3     0.615   0.680   0.328    0.380    cysteine protease inhibitor
  LGMN                                                                           Q99538       Legumain                                                             10.39   4     0.618   0.636   0.483    0.499    cysteine protease
  CPQ                                                                            Q9Y646       Carboxypeptidase Q                                                   20.55   7     0.620   0.631   0.406    0.452    carboxypeptidase activity
  CTSA                                                                           P10619       Lysosomal protective protein                                         18.75   9     0.626   0.667   0.418    0.422    serine protease
  NAGA                                                                           P17050       Alpha-*N*-acetylgalactosaminidase                                    11.92   3     0.626   0.648   0.480    0.287    deacetylase
  ENO2                                                                           P09104       Gamma-enolase                                                        60.83   11    0.631   0.676   0.436    0.494    lyase
  GALNS                                                                          P34059       *N*-acetylgalactosamine-6-sulfatase                                  8.62    5     0.633   0.687   0.436    0.377    hydrolase
  KCTD12                                                                         Q96CX2       BTB/POZ domain-containing protein KCTD12                             33.23   11    0.634   0.624   0.446    0.480    enzyme modulator
  GOLIM4                                                                         O00461       Golgi integral membrane protein 4                                    18.25   11    0.638   0.671   0.391    0.416    transport
  NMRK1                                                                          B3KN26       Nicotinamide riboside kinase 1                                       12.26   1     0.641   0.527   0.422    0.402    kinase
  RNASET2                                                                        D6REQ6       Ribonuclease T2                                                      19.27   4     0.643   0.545   0.398    0.400    endoribonuclease activity
  TUBB2B                                                                         Q9BVA1       Tubulin beta-2B chain                                                74.16   1     0.643   0.545   0.424    0.318    tubulin
  MTAP                                                                           Q13126       *S*-methyl-5′-thioadenosine phosphorylase                            71.38   15    0.645   0.683   0.484    0.492    phosphorylase
  NAGLU                                                                          P54802       Alpha-*N*-acetylglucosaminidase                                      26.11   13    0.646   0.706   0.466    0.478    glycosidase, hydrolase
  TXNIP                                                                          Q9H3M7       Thioredoxin-interacting protein                                      16.11   6     0.650   0.441   0.479    0.351    transcription regulation, oxidative stress mediator
  BCAR3                                                                          O75815       Breast cancer anti-estrogen resistance protein 3                     7.88    4     0.652   0.285   0.162    0.272    guanine-nucleotide releasing factor
  GUSB                                                                           P08236       Beta-glucuronidase                                                   26.42   16    0.678   0.649   0.495    0.452    galactosidase
  PGK1                                                                           P00558       Phosphoglycerate kinase 1                                            84.41   31    0.686   0.647   0.461    0.437    carbohydrate kinase
  H6PD                                                                           O95479       GDH/6PGL endoplasmic bifunctional protein                            35.65   23    0.708   0.729   0.477    0.483    dehydrogenase
  CSRP1                                                                          P21291       Cysteine and glycine-rich protein 1                                  64.25   9     0.711   0.670   0.426    0.427    actin family cytoskeletal protein
  CPVL                                                                           Q9H3G5       Probable serine carboxypeptidase CPVL                                21.22   9     0.711   0.640   0.480    0.453    serine protease
  NNMT                                                                           P40261       Nicotinamide *N*-methyltransferase                                   56.06   10    0.713   0.667   0.335    0.333    methyltransferase
  EXTL3                                                                          O43909       Exostosin-like 3                                                     15.34   13    0.737   0.807   0.433    0.472    glycosyltransferase
  VLDLR                                                                          P98155       Very low-density lipoprotein receptor                                8.48    6     0.738   0.699   0.460    0.478    receptor, extracellular matrix glycoprotein
  MMP14                                                                          P50281       Matrix metalloproteinase-14                                          19.76   11    0.748   0.800   0.344    0.361    hydrolase, metalloprotease, protease
  OSTF1                                                                          Q92882       Osteoclast-stimulating factor 1                                      53.74   9     0.750   0.649   0.459    0.463    signal transduction
  AKAP2                                                                          Q9Y2D5       A-kinase anchor protein 2                                            15.83   7     0.751   0.773   0.410    0.468    regulation of cell cycle, apoptosis process
  SIAE                                                                           Q9HAT2       Sialate *O*-acetylesterase                                           12.05   5     0.769   0.725   0.346    0.294    esterase
  MRC2                                                                           Q9UBG0       C-type mannose receptor 2                                            11.36   13    0.778   0.867   0.379    0.454    receptor
  IDS                                                                            P22304       Iduronate 2-sulfatase                                                23.82   9     0.784   0.812   0.425    0.465    hydrolase
  CNTNAP1                                                                        P78357       Contactin-associated protein 1                                       2.02    2     0.792   0.638   0.403    0.436    transporter, membrane-bound signaling molecule, receptor
  AKR1C3                                                                         S4R3Z2       Aldo-keto reductase family 1 member C3                               6.67    1     0.828   0.645   0.305    0.337    reductase
  AMDHD2                                                                         Q9Y303       Putative *N*-acetylglucosamine-6-phosphate deacetylase               8.07    2     0.840   0.548   0.465    0.473    deacetylase
  MANBA                                                                          O00462       Beta-mannosidase                                                     6.60    3     0.901   0.799   0.356    0.482    galactosidase
  SH3BP5L                                                                        Q7L8J4       SH3 domain-binding protein 5-like                                    5.09    2     0.912   0.931   0.354    0.411    protein kinase inhibitor
  LRP1                                                                           Q07954       Prolow-density lipoprotein receptor-related protein 1                0.62    3     1.068   0.617   0.381    0.478    receptor, extracellular matrix glycoprotein
  ATF7IP                                                                         F5GYR7       Activating transcription factor 7-interacting protein 1 (Fragment)   9.38    1     ND      0.447   0.441    0.146    transcription regulation
  VPS29                                                                          Q9UBQ0       Vacuolar protein sorting-associated protein 29                       56.04   1     ND      0.922   0.473    0.474    vesicle coat protein

^a^ The values of coverage and unique peptides are based on forward labeling result; ^b^ Ratios: Spot abundance of tachyplesin I-treated samples relative to the control; 0: control group; 10: 10 μg/mL dose group; 40: 40 μg/mL dose group; forward: forward labeling group; reverse: reverse labeling group; ^c^ Functional categories according to Gene ontology and panther biological process annotations.
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###### 

List of altered KEGG pathways with tachyplesin I treatment and their *p*-values identified by bioinformatic analysis using DAVID (*p* \< 0.1).

  Pathways                              *p* Value       Differentially Expressed Proteins Involved in This Pathway
  ------------------------------------- --------------- --------------------------------------------------------------------------------------------
  Lysosome                              1.11 × 10^−8^   SGSH, AGA, NAGLU, GUSB, LGMN, ACP5, CTSA, MANBA, ATP6V0C, GLA, IDS, GALNS, NAGA, GAA, IDUA
  Glycosaminoglycan degradation         2.53 × 10^−5^   SGSH, NAGLU, IDS, GUSB, GALNS, IDUA
  Antigen processing and presentation   5.99 × 10^−4^   TAP2, LGMN, TAP1, HLA-A, HLA-B, HLA-E, TAPBP, B2M
  DNA replication                       3.51 × 10^−3^   MCM7, MCM2, MCM4, MCM5, MCM6
  Type I diabetes mellitus              3.75 × 10^−2^   INS, HLA-A, HLA-B, HLA-E
  Glycolysis/Gluconeogenesis            8.93 × 10^−2^   TPI1, ENO2, PGK1, ENO1
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###### 

Labeling scheme of DIGE for U251 gliomaspheres protein.

  Gel No.   Cy2        Cy3   Cy5
  --------- ---------- ----- -----
  Gel 01    Standard   A1    B2
  Gel 02    Standard   B1    C3
  Gel 03    Standard   C2    D3
  Gel 04    Standard   D2    A2
  Gel 05    Standard   A3    C1
  Gel 06    Standard   B3    D1

A: control group; B: 10 μg/mL dose group; C: 40 μg/mL dose group; D: 80 μg/mL dose group; 1--3: three biological repeats in each group.
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###### 

Dimethyl-labeling scheme for U251 gliomaspheres protein.

  Samples               Forward      Reverse
  --------------------- ------------ ------------
  control group         Heavy (H)    Light (L)
  10 μg/mL dose group   Light (L)    Medium (M)
  40 μg/mL dose group   Medium (M)   Heavy (H)

[^1]: These authors contributed equally to this work.
